Design software company Adobe Inc. (NASDAQ: ADBE) is all set to report second-quarter 2024 earnings today after the closing bell. The company is currently busy integrating artificial intelligence across its platform.
Listen to Adobe’s Q2 2024 earnings call live and read the real-time transcript
Analysts’ consensus forecast for Q2 adjusted profit is $4.09 per share, compared to $3.91 per share in the three months ended May 2023. Meanwhile, Adobe executives are looking for Q2 earnings in the range of $4.35 per share to $4.40 per share. Wall Street forecasts second-quarter revenues of $4.93 billion. That falls below the management’s revenue guidance of $5.25-$5.30 billion.
In the first three months of fiscal 2024, the San Jose-based tech firm’s earnings and revenues exceeded the market’s forecast. The top line moved up 11% from the prior-year period to $5.18 billion in Q1. Consequently, adjusted earnings advanced 18% to $4.48 per share. On a reported basis, net income jumped 50% year-over-year to $620 million or $1.36 per share.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings
After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform
What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
